Meeting
2019 ASCO Annual Meeting
A phase I study of pazopanib with weekly paclitaxel and carboplatin in advanced solid tumors.
Authors
Nancy Chan
Rutgers Cancer Institute of New Jersey, New Brunswick, NJ
Nancy Chan , Daniella E. Portal , Rebecca Anne Moss , Ann W. Silk , Mark N. Stein , Joseph Aisner , Jyoti Malhotra , Weichung Shih , Hongxia Lin , Michael P. Kane , Janice M. Mehnert , Antoinette R. Tan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics and Tumor Biology (Nonimmuno)
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Cancer Angiogenesis and Metastases
Clinical Trial Registration Number
NCT01407562
Citation
J Clin Oncol 37, 2019 (suppl; abstr 3021)
DOI
10.1200/JCO.2019.37.15_suppl.3021
Abstract #
3021
Poster Bd #
13
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Phase I study of the combination of alisertib (MLN8237) and gemcitabine in advanced solid tumors.
First Author: Jasmine Huynh
Poster
2016 ASCO Annual Meeting
A phase I study of afatinib combined with carboplatin or carboplatin plus paclitaxel in patients (pts) with advanced solid tumors.
First Author: Fangfei Gao
Poster
2014 ASCO Annual Meeting
Pazopanib (P) and cisplatin (CDDP) in patients with advanced solid tumors: A UNICANCER phase I study.
First Author: Veronique Dieras
Poster
2012 ASCO Annual Meeting
Phase I and pharmacokinetic (PK) study of pazopanib (P) in combination with two schedules of ifosfamide (I) in patients (pts) with advanced solid tumors (STs).
First Author: Paul Hamberg